Designing small molecules for therapeutic success: A contemporary perspective von Maurer, Tristan S., Edwards, Martin, Hepworth, David, Verhoest, Patrick, Allerton, Charlotte M.N.

Volltext

Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route von Blagg, Julian, Allerton, Charlotte M.N., Batchelor, David V.J., Baxter, Andrew D., Burring, Denise J., Carr, Christopher L., Cook, Andrew S., Nichols, Carly L., Phipps, Joanne, Sanderson, Vivienne G., Verrier, Hugh, Wong, Stephen

Volltext

A Novel Series of Potent and Selective PDE5 Inhibitors with Potential for High and Dose-Independent Oral Bioavailability von Allerton, Charlotte M. N, Barber, Christopher G, Beaumont, Kevin C, Brown, David G, Cole, Susan M, Ellis, David, Lane, Charlotte A. L, Maw, Graham N, Mount, Natalie M, Rawson, David J, Robinson, Colin M, Street, Stephen D. A, Summerhill, Nicholas W

Volltext

In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance von Zhu, Yuao, Yurgelonis, Irina, Noell, Stephen, Yang, Qingyi, Guan, Shunjie, Li, Zhenghui, Hao, Li, Rothan, Hussin, Rai, Devendra K, McMonagle, Patricia, Baniecki, Mary Lynn, Greasley, Samantha E, Plotnikova, Olga, Lee, Jonathan, Nicki, Jennifer A, Ferre, RoseAnn, Byrnes, Laura J, Liu, Wei, Craig, Timothy K, Steppan, Claire M, Liberator, Paul, Soares, Holly D, Allerton, Charlotte M N, Anderson, Annaliesa S, Cardin, Rhonda D

Volltext

Design and synthesis of pyridazinone-based 5-HT2C agonists von ALLERTON, Charlotte M. N, ANDREWS, Mark D, WARD, Robin, WATSON, Lesa, BLAGG, Julian, ELLIS, David, EVRARD, Edel, GREEN, Martin P, LIU, Kevin K.-C, MCMURRAY, Gordon, RALPH, Michael, SANDERSON, Vivienne

Volltext

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 von Owen, Dafydd R, Allerton, Charlotte M N, Anderson, Annaliesa S, Aschenbrenner, Lisa, Avery, Melissa, Berritt, Simon, Boras, Britton, Cardin, Rhonda D, Carlo, Anthony, Coffman, Karen J, Dantonio, Alyssa, Li, Di, Eng, Heather, Ferre, RoseAnn, Gajiwala, Ketan S, Gibson, Scott A, Greasley, Samantha E, Hurst, Brett L, Kadar, Eugene P, Kalgutkar, Amit S, Lee, Jack C, Lee, Jisun, Liu, Wei, Mason, Stephen W, Noell, Stephen, Novak, Jonathan J, Obach, R Scott, Ogilvie, Kevin, Patel, Nandini C, Pettersson, Martin, Rai, Devendra K, Reese, Matthew R, Sammons, Matthew F, Sathish, Jean G, Singh, Ravi Shankar P, Steppan, Claire M, Stewart, Al E, Tuttle, Jamison B, Updyke, Lawrence, Verhoest, Patrick R, Wei, Liuqing, Yang, Qingyi, Zhu, Yuao

Volltext

Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT2c agonists von ANDREWS, Mark D, GREEN, Martin P, WATSON, Lesa, ALLERTON, Charlotte M. N, BATCHELOR, David V, BLAGG, Julian, BROWN, Alan D, GORDON, David W, MCMURRAY, Gordon, MILLNS, Daniel J, NICHOLS, Carly L

Volltext

Design, synthesis and biological activity of β-carboline-based type-5 phosphodiesterase inhibitors von Maw, Graham N., Allerton, Charlotte M.N., Gbekor, Eugene, Million, William A.

Volltext

A Second-Generation Oral SARS-CoV‑2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19 von Allerton, Charlotte M. N., Arcari, Joel T., Aschenbrenner, Lisa M., Avery, Melissa, Bechle, Bruce M., Behzadi, Mohammad Amin, Boras, Britton, Buzon, Leanne M., Cardin, Rhonda D., Catlin, Natasha R., Carlo, Anthony A., Coffman, Karen J., Dantonio, Alyssa, Di, Li, Eng, Heather, Farley, Kathleen A., Ferre, Rose Ann, Gernhardt, Steven S., Gibson, Scott A., Greasley, Samantha E., Greenfield, Siennah R., Hurst, Brett L., Kalgutkar, Amit S., Kimoto, Emi, Lanyon, Lorraine F., Lovett, Gabrielle H., Lian, Yajing, Liu, Wei, Martínez Alsina, Luis A., Noell, Stephen, Obach, R. Scott, Owen, Dafydd R., Patel, Nandini C., Rai, Devendra K., Reese, Matthew R., Rothan, Hussin A., Sakata, Sylvie, Sammons, Matthew F., Sathish, Jean G., Sharma, Raman, Steppan, Claire M., Tuttle, Jamison B., Verhoest, Patrick R., Wei, Liuqing, Yang, Qingyi, Yurgelonis, Irina, Zhu, Yuao

Volltext

An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19 von Owen, Dafydd R, Allerton, Charlotte M N, Anderson, Annaliesa S, Aschenbrenner, Lisa, Avery, Melissa, Berritt, Simon, Boras, Britton, Cardin, Rhonda D, Carlo, Anthony, Coffman, Karen J, Dantonio, Alyssa, Di, Li, Eng, Heather, Ferre, RoseAnn, Gajiwala, Ketan S, Gibson, Scott A, Greasley, Samantha E, Hurst, Brett L, Kadar, Eugene P, Kalgutkar, Amit S, Lee, Jack C, Lee, Jisun, Liu, Wei, Mason, Stephen W, Noell, Stephen, Novak, Jonathan J, Obach, R Scott, Ogilvie, Kevin, Patel, Nandini C, Pettersson, Martin, Rai, Devendra K, Reese, Matthew R, Sammons, Matthew F, Sathish, Jean G, Singh, Ravi Shankar P, Steppan, Claire M, Stewart, Al E, Tuttle, Jamison B, Updyke, Lawrence, Verhoest, Patrick R, Wei, Liuqing, Yang, Qingyi, Zhu, Yuao

Volltext

Design and synthesis of pyridazinone-based 5-HT sub(2C) agonists von Allerton, Charlotte MN, Andrews, Mark D, Blagg, Julian, Ellis, David, Evrard, Edel, Green, Martin P, Liu, Kevin K-C, McMurray, Gordon, Ralph, Michael, Sanderson, Vivienne, Ward, Robin, Watson, Lesa

Volltext

Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT sub(2C) agonists von Andrews, Mark D, Green, Martin P, Allerton, Charlotte MN, Batchelor, David V, Blagg, Julian, Brown, Alan D, Gordon, David W, McMurray, Gordon, Millns, Daniel J, Nichols, Carly L, Watson, Lesa

Volltext

Design and synthesis of pyridazinone-based 5-HT(2C) agonists von Allerton, Charlotte M N, Andrews, Mark D, Blagg, Julian, Ellis, David, Evrard, Edel, Green, Martin P, Liu, Kevin K-C, McMurray, Gordon, Ralph, Michael, Sanderson, Vivienne, Ward, Robin, Watson, Lesa

Volltext

Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT(2C) agonists von Andrews, Mark D, Green, Martin P, Allerton, Charlotte M N, Batchelor, David V, Blagg, Julian, Brown, Alan D, Gordon, David W, McMurray, Gordon, Millns, Daniel J, Nichols, Carly L, Watson, Lesa

Volltext

Supplementary data for the manuscript: An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19 von Owen, Dafydd R., M. N. Allerton, Charlotte, Anderson, Annaliesa S., Aschenbrenner, Lisa, Avery, Melissa, Berritt, Simon, Boras, Britton, Cardin, Rhonda D., Carlo, Anthony, Coffman, Karen J., Dantonio, Alyssa, Di, Li, Eng, Heather, Ferre, RoseAnn, Gajiwala, Ketan S., Gibson, Scott, Greasley, Samantha E., L. Hurst, Brett, Kadar, Eugene, Kalgutkar, Amit S., Lee, Jack C., Lee, Jisun, liu, wei, Mason, Stephen W., Noell, Stephen, Novak, Jonathan J., Obach, R. Scott, Ogilvie, Kevin, Patel, Nandini C., Pettersson, Martin, K. Rai, Devendra, Reese, Matthew R., Sammons, Matthew F., sathish, jean, Singh, Ravi Shankar, Steppan, Claire M., Stewart, Al e., Tuttle, Jamison B., Updyke, Lawrence, Verhoest, Patrick R., Wei, Liuqing, Yang, Qingyi, Zhu, Yuao

Volltext bestellen

PYRAZOLO[4,3-D]PYRIMIDINON-VERBINDUNGEN ALS CGMP PDE-INHIBITOREN von BARBER, CHRISTOPHER G, ALLERTON, CHARLOTTE M. N, KEMP, MARK I

Volltext bestellen

PYRAZOLO(4,3-D)PYRIMIDINON-VERBINDUNGEN ALS CGMP PDE-INHIBITOREN von BARBER, CHRISTOPHER G, ALLERTON, CHARLOTTE M. N, KEMP, MARK I

Volltext bestellen

PYRAZOLO[4,3-D]PYRIMIDINONE COMPOUNDS AS CGMP PDE INHIBITORS von BARBER, CHRISTOPHER G, ALLERTON, CHARLOTTE M. N, KEMP, MARK I

Volltext bestellen

Design, Synthesis and Biological Activity of β-Carboline-Based Type-5 Phosphodiesterase Inhibitors von Maw, Graham N., Allerton, Charlotte M. N., Gbekor, Eugene, Million, William A.

Volltext

IMIDAZO-TRIAZINE DERIVATIVES AS PDE 5 INHIBITORS von ALLERTON, CHARLOTTE M. N, DACK, KEVIN NEIL, KEMP, MARK IAN

Volltext bestellen